Stem cells may not systematically obey traditional Phase I-IV clinical translation models. In response, various actors have suggested that stem cell-based medical innovation models could catalyze translation instead. Accordingly, calls were made to adopt more permissive approaches to stem cell translation. Yet, the Phase I-IV paradigm remains the standard within the scientific community. This article seeks to advance the stalemated discussions by proposing an alternative model for consideration. In it, we argue that a stem cell-based learning health system may be able to reconcile these two models. Centered on the acceleration of evidence and knowledge flow, a stem cell-based learning health system could maximize patient retention and data follow-up, thereby promoting inclusive system learning and improvement.
No takes yet. Share an insight, caveat, or question.
Touré et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: